1472 results
Coronary Interventions: EuroPCR 2025 highlights
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Rasha Al-Lamee, Nieves Gonzalo, and Thomas Cuisset highlighted key advances in coronary interventions, with a strong emphasis on managing complex cases—particularly calcified lesions.
Throughout the Course, LIVE cases and expert hotlines showcased dedicated devices and evolving strategies designed specifically for these challenging lesions. Advanced...

Structural and Valvular Interventions: EuroPCR 2025 highlights
22 May 2025 – From EuroPCR 2025
Christopher Cook, Nicolas Dumonteil, and Bernard Prendergast share their top EuroPCR 2025 highlights in structural heart interventions. Challenging cases like re-do TAVI, coronary re-access difficulties, and leaflet modification took center stage in case-based and LIVE sessions. Cutting-edge research was featured too, including a meta-analysis combining the...

TAVI and the left ventricular myocardium
23 May 2025 – From EuroPCR 2025
Understand the intricate relationship between TAVI and left ventricular myocardium through discussions on cardiac damage stages, functional remodeling, and pharmacological interventions post-TAVR. This session also reviews prophylactic ECMO support in high-risk patients, offering a comprehensive perspective on optimizing TAVI outcomes.

Permanent pacing after TAVI
23 May 2025 – From EuroPCR 2025
Explore predictors and mechanisms leading to permanent pacemaker implantation after TAVI. This session reviews electrophysiological intervals, atrial pacing markers, anatomical risk factors, and outcomes associated with new generation transcatheter heart valves.

High-risk PCI in TAVI procedures
23 May 2025 – From EuroPCR 2025
This session highlights high-risk PCI in the context of TAVI procedures, including hybrid approaches for aortic stenosis with coronary disease, valve-in-valve scenarios, and unique anatomical challenges such as total situs inversus, emphasizing comprehensive patient management.

TAVI for bioprosthetic valve failure - LIVE Case
22 May 2025 – From EuroPCR 2025
A 68-year-old male patient with a history of Sapien 3 26 mm TAVI (2021), complicated by the need for two valves (one displaced in the descending aorta) and permanent pacemaker implantation, as well as endocarditis (2022), presented with symptomatic bioprosthesis failure and reduced LV function (20...

Hotline TAVI 3: Challenging anatomical and clinical scenarios
22 May 2025 – From EuroPCR 2025
This hotline session presents challenging anatomical and clinical scenarios in TAVI, including outcomes in bicuspid aortic valve patients, chronic aortic regurgigation, comparisons of surgical versus percutaneous approaches, and real-world data on valve performance and resource utilization.
Inludes:
- Five-year outcomes from the Evolut low risk TAVR bicuspid study
- Surgical versus...

Managing difficult problems during TAVI procedures
22 May 2025 – From EuroPCR 2025
This session reviews difficult problems and complications encountered during TAVI procedures. Learn from real-world cases, expert treatment strategies, and key takeaways to enhance management and improve patient outcomes in challenging scenarios.

TAVI - Head-to-head comparative studies
22 May 2025 – From EuroPCR 2025
Compare head-to-head outcomes of various TAVI devices through real-world registries and meta-analyses. This session provides insights into performance differences between self-expanding and balloon-expandable valves to inform clinical decision-making.

Valve choice - Shaping index procedures and lifetime patient management
22 May 2025 – From EuroPCR 2025
This session addresses recent advancements and ongoing challenges in transcatheter aortic valve implantation (TAVI), with a particular focus on valve selection during index procedures. Presentations include data from the Accurate IDE trial, highlighting the prognostic implications of valve underexpansion. A clinical case involving an 80-year-old patient with severe...

The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...

How to optimise TAVI outcomes in the Asian-Pacific population?
22 May 2025 – From EuroPCR 2025
What are the key considerations for TAVI in Asian-Pacific patients? This EuroPCR 2025 session focuses on optimising outcomes in anatomically and clinically specific contexts, such as patients with small annuli. Learn how the latest intra-annular self-expanding devices can help reduce post-procedural pacemaker implantation (PPI) rates, and...

Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.

TAVI in women
22 May 2025 – From EuroPCR 2025
Focus on gender-specific considerations in TAVI with this session. Topics include timely management and referral disparities in women with severe aortic stenosis, early outcomes from the LANDMARK trial with latest-generation valves, insights from NAVULTRA comparing valve types, prosthesis-patient mismatch data, and gender differences in right ventricular...

Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...

Management of challenging TAVI device delivery
22 May 2025 – From EuroPCR 2025
Explore innovative solutions for managing challenging TAVI device delivery. This session presents cases involving kinked and stuck Navitor valves, the use of snare devices for retrieval, balloon-expandable TAVI in severe bicuspid aortic stenosis, and alternative access routes such as transaortic access after failed transfemoral valve-in-valve procedures.

TAVI - Outcomes predictors
22 May 2025 – From EuroPCR 2025
Examine novel predictors of outcomes following TAVI. This session compares a new nutritional risk index against traditional scores for early post-TAVI mortality prediction and evaluates uric acid as a marker for aortic valve calcification and mortality risk in TAVI patients.

TAVI for aortic regurgitation off label
22 May 2025 – From EuroPCR 2025
Explore off-label applications of TAVI for aortic regurgitation in complex clinical scenarios. Topics include TAV-in-SAV with Trilogy valve for severe regurgitation, challenges of transcatheter prosthesis in pure aortic regurgitation, management of surgical valve perforations, and treatment strategies in post-surgical anatomies including degenerative homografts and aortic dissection.

Redo TAVI - How to treat different TAVI platforms when they fail
22 May 2025 – From EuroPCR 2025
Understand the complexities of redo TAVI procedures with emphasis on planning, valve platform characteristics, and tailored procedural strategies. This session features cases of redo TAVI for failed short-frame and tall-frame valves, alongside discussions on current evidence gaps guiding optimal management.

Optimising self-expandable TAVI clinical outcomes without compromise
22 May 2025 – From EuroPCR 2025
Optimising patient outcomes in self-expandable TAVI starts with a clear plan for today, and tomorrow. This EuroPCR 2025 session explores how to make each step count, from access to implantation and closure, using a real-life case of a 77-year-old woman with severe symptomatic aortic stenosis and...
